BPC-157 Research Guide: Mechanism and Studies (2026)

What is BPC-157?

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a protective protein found naturally in human gastric juice. The amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of approximately 1,419 Daltons.

Unlike many peptides used in research, BPC-157 demonstrates notable stability in acidic environments — a property attributed to its gastric juice origins. This characteristic has attracted sustained attention from gastrointestinal researchers.

Full Name	Body Protection Compound-157
Type	Synthetic Pentadecapeptide
Amino Acids	15 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)
Molecular Weight	~1,419 Da
Origin	Derived from human gastric juice protein
Stability	Stable in acidic environments (pH 2–4)
Form	Lyophilized powder (research grade)

Key research areas

Gastrointestinal research

The most extensively studied application of BPC-157 involves gastrointestinal tissue. In animal models, researchers have characterized its interaction with gastric mucosal tissue exposed to agents such as NSAIDs and alcohol. Reported observations include cytoprotective activity, with effects on mucosal integrity and blood vessel formation in gastric tissue.

Musculoskeletal research

A growing body of preclinical research has examined BPC-157’s interaction with tendon, ligament, muscle, and bone tissue. Researchers have reported effects on fibroblast activity and collagen organization in these models.

Angiogenesis pathway research

Several research groups have investigated BPC-157’s relationship with angiogenesis — the formation of new blood vessels. Preclinical studies have examined its interaction with the VEGF (vascular endothelial growth factor) pathway. Hsieh et al. (Journal of Molecular Medicine, 2017) documented the VEGFR2 activation mechanism specifically.

Neuroprotective research

Emerging preclinical research has explored BPC-157’s potential interactions with the nervous system. Some animal studies suggest possible effects on dopaminergic and serotonergic systems, though this area remains in early stages. Researchers have also examined its potential in models of peripheral nerve damage. Vukojevic et al. (Neural Regeneration Research, 2022) provides a useful review of the CNS-related findings.

Nitric oxide system interactions

Research indicates that BPC-157 may interact with the nitric oxide (NO) system, which plays roles in vasodilation, immune response, and neurotransmission. Understanding these interactions is an active area of peptide research.

Research methodology considerations

When working with BPC-157 in research settings, several factors matter. Research-grade BPC-157 should have ≥99% purity verified by HPLC, with mass spectrometry confirmation of molecular identity. Proper experimental design requires vehicle controls and, where possible, positive controls.

Storage and handling

Proper storage protocol

Lyophilized (powder form): Store at -20°C for optimal long-term stability. BPC-157 is relatively stable but benefits from cold storage to prevent degradation over months.

Reconstituted (liquid form): Store at 2–8°C (standard refrigeration) and use within 2–4 weeks. Use bacteriostatic water as the reconstitution solvent for its preservative properties.

Protect from light: UV exposure accelerates peptide degradation. Store in amber vials or wrap in foil.

Current state of research

The majority of published BPC-157 research has been conducted in animal models. Human clinical trials remain limited. The mechanistic picture is still developing — particularly in the neurological and cardiovascular areas — and researchers should consult the latest peer-reviewed literature rather than extrapolating from the existing animal data.

Research use disclaimer

BPC-157 is sold strictly for in vitro and in vivo research purposes only. It is not intended for human consumption, therapeutic use, or self-administration. All information presented here is for educational and research reference purposes. Researchers should comply with all applicable regulations and institutional review requirements. CertaPeptides does not make any claims regarding therapeutic efficacy in humans.

Recent BPC-157 research: neurological and cardiovascular findings

Recent years have seen BPC-157 research expand into areas beyond its established gastrointestinal and musculoskeletal applications. The neurological findings are worth noting for researchers working in adjacent areas.

Neuroinflammation and nervous system research

Preclinical studies have investigated BPC-157’s effects on glial cell behavior in neural injury models. The primary observations concern microglial polarization — specifically a shift from pro-inflammatory M1 phenotype toward M2 phenotype. Researchers have also documented effects on blood-brain barrier integrity in injury models, including tight junction stability and inflammatory infiltration. Whether these effects translate beyond rodent models remains an open question.

Vukojevic et al. (Neural Regeneration Research, 2022) covers the CNS mechanisms in detail if this area is relevant to your research program. The data is preclinical, but the consistency across different injury models is notable.

Cardiovascular and endothelial effects

A separate body of work has examined BPC-157 in cardiovascular models, reporting effects on vascular endothelial function, nitric oxide production, and vasodilation in preclinical settings. Effects on coagulation parameters reported in some studies require further characterization in terms of mechanism. This work remains primarily in animal models.

Metabolic observations

Some preclinical work has examined BPC-157’s effects on insulin signaling, mitochondrial function, and lipid profiles in metabolic models. The data is early and the sample sizes are small.

Combination protocols in research

Researchers have examined BPC-157 alongside other peptides, drawing on their complementary mechanisms. The BPC-157 + TB-500 pairing is the most studied in the literature, on the basis that BPC-157’s angiogenic signaling and TB-500’s cell migration activity engage different molecular pathways. For context on comparing these compounds, see our BPC-157 vs TB-500 comparison guide.

FAQ

References

Sikiric P, et al. (2014). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 20(7), 1023-1035. PMID: 23701538.
Sikiric P, et al. (2006). Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model. Life Sciences, 79(5), 483-489. PMID: 16516235.
Seiwerth S, et al. (2014). BPC 157 effect on healing. Journal of Physiology – Paris, 108(2-3), 94-109. PMID: 24075973.
Staresinic M, et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. Journal of Orthopaedic Research, 21(6), 976-983. PMID: 14554208.
Hsieh MJ, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323-333. PMID: 27866220.
Sikiric P, et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157: Gastrointestinal and Brain Effects. Current Neuropharmacology, 16(8), 1116-1145. PMID: 29651949.
Vukojevic J, et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 17(3), 482-487. PMID: 34380875.
Sikiric P, et al. (2023). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 14, 1128548. PMID: 37007028.